177 related articles for article (PubMed ID: 18322167)
41. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.
Raziorrouh B; Ulsenheimer A; Schraut W; Heeg M; Kurktschiev P; Zachoval R; Jung MC; Thimme R; Neumann-Haefelin C; Horster S; Wächtler M; Spannagl M; Haas J; Diepolder HM; Grüner NH
Gastroenterology; 2011 Oct; 141(4):1422-31, 1431.e1-6. PubMed ID: 21763239
[TBL] [Abstract][Full Text] [Related]
42. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C.
Kaplan DE; Sugimoto K; Ikeda F; Stadanlick J; Valiga M; Shetty K; Reddy KR; Chang KM
Hepatology; 2005 Jun; 41(6):1365-75. PubMed ID: 15915458
[TBL] [Abstract][Full Text] [Related]
43. CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C.
Welker MW; Hofmann WP; Lange CM; Herrmann E; Sarrazin C; Zeuzem S; Kronenberger B
Scand J Gastroenterol; 2011 Jul; 46(7-8):973-80. PubMed ID: 21615225
[TBL] [Abstract][Full Text] [Related]
44. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
Rozenberg L; Haagmans BL; Neumann AU; Chen G; McLaughlin M; Levy-Drummer RS; Masur H; Dewar RL; Ferenci P; Silva M; Viola MS; Polis MA; Kottilil S
AIDS; 2009 Nov; 23(18):2439-50. PubMed ID: 19898214
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
47. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
48. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the relationship between peripheral blood T lymphocyte subsets and HCV RNA levels in patients with chronic hepatitis C.
Huang Y; Zheng MJ; Xu YH
Genet Mol Res; 2015 Aug; 14(3):10057-63. PubMed ID: 26345942
[TBL] [Abstract][Full Text] [Related]
50. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Howell CD; Gorden A; Ryan KA; Thompson AJ; Ibrahim C; Fried M; Afdhal NH; McHutchison JG; Shianna KV; Goldstein DB; Shuldiner AR; Mitchell BD
J Hepatol; 2012 Mar; 56(3):557-63. PubMed ID: 22027585
[TBL] [Abstract][Full Text] [Related]
51. [Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].
Cai RT; Shen L; Zhao W; Yang YF; Zhang YC
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):261-6. PubMed ID: 24021786
[TBL] [Abstract][Full Text] [Related]
52. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
[TBL] [Abstract][Full Text] [Related]
53. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8
Peña-Asensio J; Calvo H; Torralba M; Miquel J; Sanz-de-Villalobos E; Larrubia JR
Cells; 2021 Mar; 10(3):. PubMed ID: 33802622
[TBL] [Abstract][Full Text] [Related]
54. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
[TBL] [Abstract][Full Text] [Related]
55. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.
Kim KA; Lin W; Tai AW; Shao RX; Weinberg E; De Sa Borges CB; Bhan AK; Zheng H; Kamegaya Y; Chung RT
J Hepatol; 2009 Apr; 50(4):705-11. PubMed ID: 19231005
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Gardiner D; Lalezari J; Lawitz E; DiMicco M; Ghalib R; Reddy KR; Chang KM; Sulkowski M; Marro SO; Anderson J; He B; Kansra V; McPhee F; Wind-Rotolo M; Grasela D; Selby M; Korman AJ; Lowy I
PLoS One; 2013; 8(5):e63818. PubMed ID: 23717490
[TBL] [Abstract][Full Text] [Related]
57. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.
Urbani S; Amadei B; Tola D; Massari M; Schivazappa S; Missale G; Ferrari C
J Virol; 2006 Nov; 80(22):11398-403. PubMed ID: 16956940
[TBL] [Abstract][Full Text] [Related]
58. Imprinted immune abnormalities in liver transplant patients cured of hepatitis C with antiviral drugs.
Doyle EH; Aloman C; El-Shamy A; Eng FJ; Kim-Schulze S; Rahman A; Schiano T; Heeger P; Branch AD
Liver Transpl; 2024 Jul; 30(7):728-741. PubMed ID: 38315053
[TBL] [Abstract][Full Text] [Related]
59. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.
Feng B; Yang RF; Zhang HY; Luo BF; Kong FY; Rao HY; Jin Q; Cong X; Wei L
Braz J Infect Dis; 2015; 19(4):390-8. PubMed ID: 26100438
[TBL] [Abstract][Full Text] [Related]
60. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection.
Jeong HY; Lee YJ; Seo SK; Lee SW; Park SJ; Lee JN; Sohn HS; Yao S; Chen L; Choi I
J Leukoc Biol; 2008 Mar; 83(3):755-64. PubMed ID: 18086898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
